Januvia

Sitagliptin, the active ingredient in Januvia, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It is prescribed to improve glycaemic control in adults with type 2 diabetes mellitus, often as part of a comprehensive diabetes management plan. It works by enhancing the body's natural incretin system, thereby increasing insulin secretion in response to meals.

GNH USA supplies Januvia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and regulatory requirements across multiple markets.

Sitagliptin is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus.

Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels. Type 2 diabetes mellitus (combination therapy): used with metformin or other agents to achieve target HbA1c. Type 2 diabetes mellitus (adjunct to lifestyle): supports diet and exercise in glycaemic management.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nasal passages and throat. - Headache: transient cranial pain of varying intensity. - Upper respiratory tract infection: symptoms such as cough and sore throat. - Nausea: occasional feeling of stomach upset. - Diarrhea: loose stools that may be self‑limiting.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Joint pain: unexplained arthralgia that may be persistent. - Hypoglycaemia (when combined with insulin or sulfonylureas): low blood glucose episodes. - Elevated liver enzymes: potential hepatic involvement requiring monitoring.

Before initiating therapy, consider the following precautions: - Assess renal function: dose may need adjustment in patients with renal impairment. - Monitor for pancreatitis: discontinue if severe abdominal pain occurs. - Evaluate for hypersensitivity: stop treatment if rash, angioedema, or other allergic signs develop. - Review cardiovascular status: no specific contraindication, but monitor patients with existing heart disease. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original packaging.

Sitagliptin may interact with several medicines; awareness of the following is important.

Major Interactions (Avoid): - Strong CYP2C8 inhibitors: may increase sitagliptin exposure. - Concomitant insulin or sulfonylureas: heightened risk of hypoglycaemia. - GLP‑1 receptor agonists: may amplify gastrointestinal adverse effects.

Moderate Interactions (Monitor Closely): - Diuretics: potential impact on glucose control. - Rifampin: may reduce sitagliptin plasma concentrations. - ACE inhibitors: monitor renal function when used together.